Page last updated: 2024-11-10

zankiren hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zankiren hydrochloride: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3086651
CHEMBL ID2105775
SCHEMBL ID121553
MeSH IDM0206685

Synonyms (20)

Synonym
zankiren hydrochloride (usan)
138810-64-7
D03745 ,
zankiren hydrochloride
fb7rz4huhj ,
4-thiazolepropanamide, n-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-((2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, monohydrochloride, (1s-(1r*,(r*(r*)),2s*,3r*))-
(s)-n-(1s,2r,3s)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha((alphas)-alpha-(((4-methyl-1-piperazinyl)sulfonyl)methyl)hydrocinnamamido)-4-thiazolepropionamide monohydrochloride
abbott-72517
4-thiazolepropanamide, n-((1s,2r,3s)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-(((2s)-2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, monohydrochloride, (alphas)-
zankiren hcl
4-thiazolepropanamide, n-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-((2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, monohydrochloride, (1s-(1r*(r*(r*)),2s*,3r*))-
zankiren hydrochloride [usan]
unii-fb7rz4huhj
CHEMBL2105775
4-thiazolepropanamide, n-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-.alpha.-((2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, monohydrochloride, (1s-(1r*,(r*(r*)),2s*,3r*))-
(s)-n-(1s,2r,3s)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-alpha[(alphas)-alpha-[[(4-methyl-1-piperazinyl)sulfonyl]methyl]hydrocinnamamido]-4-thiazolepropionamide monohydrochloride
zankiren hydrochloride [who-dd]
SCHEMBL121553
DTXSID50160800
Q27277907

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Peptidic renin inhibitors have been poorly absorbed across the intestine or rapidly eliminated by the liver and have been reported to have oral bioavailabilities of less than 2%."( Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy.
Baker, WR; Barlow, J; Cohen, J; Kleinert, HD; Klinghofer, V; Kovar, P; Polakowski, J; Rosenberg, SH; Spina, K; Stein, HH, 1992
)
0.28
"Zankiren HCl (A-72517) is a potent renin inhibitor shown to have substantial bioavailability in several animal species and to produce dose-related reductions in blood pressure, plasma renin activity, and angiotensin II (Ang II) in salt-depleted dogs."( Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects.
Boger, RS; Glassman, HN; Guyene, TT; Kleinert, HD; Ménard, J; Moyse, DM, 1995
)
0.29
" It is an orally bioavailable candidate which is being developed for oral as well as intravenous use."( Parenteral formulation development of renin inhibitor Abbott-72517.
Gupta, SL; Jones, DL; Partipilo, RW; Patel, JP,
)
0.13
"Employing a set of empirical guidelines for the design of well-absorbed renin inhibitors, we have followed two strategies to improve potency while maintaining bioavailability."( Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyc
Barlow, JL; Cohen, J; Condon, SL; Klinghofer, V; Kovar, P; Polakowski, J; Rosenberg, SH; Spina, KP; Stein, HH; Yao, Z, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (77.78)18.2507
2000's2 (22.22)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.56 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (18.18%)5.53%
Reviews3 (27.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (54.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]